GSK to acquire Sitari

GlaxoSmithKline has agreed to acquire Sitari Pharmaceuticals, a developer of a treatment for celiac disease. No financial terms were disclosed. Sitari was incubated at COI Pharmaceuticals, which was established by Avalon Ventures.

ByIris Dorbian

11 September 2019•3 mins read

[data-article-body-skeleton]{display:none!important}

JavaScript is required to read this article. Please enable it in your browser and reload the page.

Deals North America US Healthcare Briefs

GSK to acquire Sitari

Avalon Ventures

Avalon Ventures

Related articles